Browse medicines, page 43 of 49

Use listed on the medicine record

The following infections

Use listed on the medicine record

The short-term treatment of insomnia

Use listed on the medicine record

The signs and symptoms of benign prostatic hyperplasia

Use listed on the medicine record

To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Use listed on the medicine record

Redness of the eye due to minor eye irritations

Use listed on the medicine record

• treats vaginal yeast infections

Use listed on the medicine record

Cystine stone formation

Use listed on the medicine record

Relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies

Use listed on the medicine record

Spasticity

Use listed on the medicine record

Clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic

Use listed on the medicine record

Temporarily relieves occasional feelings of exhaustion when recovering from an illness, general weakness, and low iron levels. Temporarily supports your body when dealing with growth problems, including late tooth growth and broken bones. It also temporarily supports thin individuals.* *CLAIMS BASED ON TRADITIONAL HOMEOPATHIC PRACTICE, NOT ACCEPTED MEDICAL EVIDENCE. NOT FDA EVALUATED. This product is not intended to diagnose, treat, cure, or prevent any disease.

Use listed on the medicine record

Indications & Usage ■ temporarily protects minor ■ rashes ■ cracked skin ■ red bumps ■ helps prevent and temporarily protects and helps relieve ■ chapped or cracked skin ■ helps prevent and protect from the drying effects of wind and cold weather ■ temporarily protects and helps relieve minor skin irritation and itching due to ■ rashes ■ eczema ■ psoriasis ■ rough elbows ■ cracked hands ■ cracked feet ■ rashes caused by soaps, detergents, cosmetics, or jewelry

Use listed on the medicine record

Symptoms of depression

Use listed on the medicine record

Fatigue, sadness, diminished memory, anxiousness, difficulty focusing, general weakness, apathy, mood swings, or irritability

Use listed on the medicine record

Hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris

Use listed on the medicine record

VABOMERE (meropenem and vaborbactam) is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 ) 1.1.

Use listed on the medicine record

Intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder

Use listed on the medicine record

Erectile dysfunction

Use listed on the medicine record

Long-term enzyme replacement therapy

Use listed on the medicine record

Major depressive disorder

Use listed on the medicine record

ROMVIMZA is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. ROMVIMZA is a kinase inhibitor indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. ( 1 )

Use listed on the medicine record

Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II.

Use listed on the medicine record

Metastatic NSCLC Vinorelbine Injection is a vinca alkaloid indicated

Use listed on the medicine record

Minor arthritis pain in the wrist*

Use listed on the medicine record

Cyanocobalamin Nasal Spray is indicated for: Vitamin B12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement Treatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B12 deficiency not due to pernicious anemia Prevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements in excess of normal Limitations of Use: Cyanocobalamin Nasal Spray should not be used for the vitamin B12 absorption test (Schilling test).

Use listed on the medicine record

Cutaneous manifestations

Use listed on the medicine record

Linear growth

Use listed on the medicine record

Complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible microorganisms

Use listed on the medicine record

Locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor

Use listed on the medicine record

KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options. ( 1 )

Use listed on the medicine record

(To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum .

Use listed on the medicine record

Elevated serum total and LDL-C

Use listed on the medicine record

Insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see Clinical Studies (14

Use listed on the medicine record

Moderate to severe vasomotor symptoms due to menopause